Incyte, Merck report additional Phase III data of epacadostat combo for melanoma

Incyte Corp. (NASDAQ:INCY) and partner Merck & Co. Inc. (NYSE:MRK) reported additional data from the Phase III ECHO-301/KEYNOTE-252 trial to treat melanoma showing that first-line treatment with

Read the full 273 word article

User Sign In